CA-NEXA3D
6.9.2022 16:01:47 CEST | Business Wire | Press release
Nexa3D, the leading maker of ultrafast professional and industrial polymer 3D printers, today announced its plans to exhibit at IMTS, taking place September 12-17 in Chicago, Illinois. For its first showing at IMTS, Nexa3D is bringing its full – and rapidly expanding - additive manufacturing portfolio to Chicago.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220906005132/en/
The full suite of Nexa3D additive manufacturing solutions will be showcased at IMTS 2022, Additive Manufacturing Pavilion, Booth #432504 (Photo: Business Wire)
Among the real-world use cases highlighted at the booth will be the work with Applied Rapid Technologies (ART), where Nexa3D will demonstrate the benefits of owning the industrial 3D printing fleet for an on-demand manufacturing operation that replaces traditional urethane casting. Ultrafast, high performance resin 3D printing enables companies like ART to serve its customers’ needs in a more cost-effective manner and at a fraction of the time typically associated with traditional manufacturing methods. “Being a service provider with the Nexa3D machines - having 8 of them online now - just gives us more flexibility to take on projects and turn them around quickly. For years, we called this rapid prototyping, but it has really morphed into additive manufacturing,” said Bruce LeMaster, Vice President of Manufacturing at Obsidian Solutions Group.
“Nexa3D’s rapidly expanding product portfolio of ultrafast industrial solutions for the entire product life cycle democratizes access to industrial strength additive manufacturing tools, materials, and workflows for the benefit of small and large users. With no end in sight to persisting supply chain shortages, small and large product companies are more ready than ever before to explore digital manufacturing solutions and we are here to assist,” said Avi Reichental, CEO, and co-founder of Nexa3D.
Nexa3D’s end-to-end validated workflows, comprising its NexaX software platform, expanding functional polymer materials, and automated post processing deliver orders of magnitude better throughput and total cost of ownership advantages to businesses that are seeking to nearshore or localize parts of their supply chain operations. The company plans to showcase its latest industrial shop printers including its flagship NXE 400 and NXE 200 ultrafast 3D printers alongside its xCure, and xClean post-processing tools. The company also plans to introduce several new functional resins at the show.
As part of its rapidly expanding portfolio of manufacturing solutions, Nexa3D also plans to demonstrate the full power of its ultrafast XiP 3D printer in a production cell configuration, showcasing industry leading throughput, cost effectiveness, and functional material selection, powered by its open source platform enabling hyperlocal, flexible manufacturing.
The company plans to commercially launch previously announced QLS 820 high-productivity industrial sintering solution along with a powder processing system at IMTS. Designed for higher operating temperatures and broader powder processing windows, the QLS 820 offers the highest part throughput in its class, delivering unprecedented production throughput and flexibility. The system is a compelling alternative to traditional injection molding, designed with integration-ready Industry 4.0, lights-out manufacturing capabilities.
Nexa3D plans to take center stage on Wednesday, Sept. 14 at 1:00PM alongside its customer, PepsiCo, to talk about the latest manufacturing innovations in packaging design and development made possible by its ultrafast NXE 400 3D printers. More information and registration details available here.
As part of IMTS, the company plans to make several significant product commercialization announcements throughout the week from the show floor.
To learn more about the additive manufacturing solutions Nexa3D plans to exhibit at IMTS view the media kit.
About Nexa3D
Nexa3D is passionate about digitizing supply chains sustainably. The company makes ultrafast polymer 3D printers that deliver up to 20x productivity gains to professionals and businesses of all sizes. Partnerships with world-class material suppliers and its open materials platform unlock the full potential of additively manufactured polymers for volume production. Automated software tools optimize the entire production cycle using process interplay algorithms that ensure part performance and production consistency, while reducing waste, energy, and minimizing carbon footprints.
For more information on Nexa3D and its products, visit the Nexa3D website, or connect socially on LinkedIn, Twitter, Facebook, and Instagram.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220906005132/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom